
April 30 (Reuters) - SANDOZ GROUP AG SDZ.S:
SANDOZ Q1 SALES USD 2,480 MILLION
REPORTS Q1 2025 NET SALES IN LINE WITH COMPANY EXPECTATIONS; FULL-YEAR GUIDANCE CONFIRMED
FULL-YEAR 2025 GUIDANCE CONFIRMED: MID SINGLE-DIGIT NET-SALES GROWTH AND CORE EBITDA MARGIN OF AROUND 21%
FULL-YEAR IMPACT OF US GOVERNMENT'S CONFIRMED RECENT TARIFFS WITHIN GUIDANCE
US FIRST-QUARTER NET SALES REPRESENTED LESS THAN ONE-FIFTH OF TOTAL NET Q1 SALES
DECIDED TO MINIMIZE ONGOING PHASE III TRIAL IN PATIENTS WITH UNTREATED METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER FOR PROPOSED BIOSIMILAR, PEMBROLIZUMAB
COMPANY IS ASSESSING IMPLICATIONS, INCLUDING FOR ITS WIDER BIOSIMILARS PIPELINE